Loading
A phase 3 trial testing PM8002 in small-cell lung cancer and non-small-cell lung cancer, active and no longer recruiting.
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06616532, led by Biotheus, and active but no longer recruiting on the registry. Official title: A Multicenter, Open-lable, Randomised Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer. Planned enrolment is 404 participants (estimated). The study started in 2024-11-13 and primary completion is expected in 2027-01-25. No results have been posted on ClinicalTrials.gov.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.